Görlitz, Anke

[["dc.bibliographiccitation.journal","JDDG Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Brehmer, Franziska"],["dc.contributor.author","Haenssle, Holger Andreas"],["dc.contributor.author","Daeschlein, G."],["dc.contributor.author","Ahmed, R."],["dc.contributor.author","Pfeiffer, S."],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Simon, D."],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Wandke, Dirk"],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T09:19:10Z"],["dc.date.available","2018-11-07T09:19:10Z"],["dc.date.issued","2013"],["dc.format.extent","10"],["dc.identifier.isi","000324332500029"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28574"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.issn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.title","The Treatment of chronic venous Leg Ulcers with direct Plasma (PlasmaDerm (R) VU 2010): Results of a single center, two-arm, open-label, randomized, controlled Trial"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Experimental Dermatology"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Brehmer, Franziska"],["dc.contributor.author","Haenssle, Holger Andreas"],["dc.contributor.author","Daeschlein, G."],["dc.contributor.author","Ahmed, R."],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Simon, D."],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Wandke, Dirk"],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T09:27:22Z"],["dc.date.available","2018-11-07T09:27:22Z"],["dc.date.issued","2013"],["dc.format.extent","E11"],["dc.identifier.isi","000316332000063"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30517"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","40th Annual Meeting of the Association-of-Dermatological-Research"],["dc.relation.eventlocation","Dessau, GERMANY"],["dc.relation.issn","0906-6705"],["dc.title","Treatment of chronic venous leg ulcers with a hand-held DBD plasma generator (PlasmaDerm (R) VU-2010): results of a monocentric, two-armed, open, randomized, and controlled trial (NCT01415622)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","148"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of the European Academy of Dermatology and Venereology"],["dc.bibliographiccitation.lastpage","155"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Brehmer, Franziska"],["dc.contributor.author","Haenssle, Holger Andreas"],["dc.contributor.author","Daeschlein, G."],["dc.contributor.author","Ahmed, R."],["dc.contributor.author","Pfeiffer, S."],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Simon, D."],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Wandke, Dirk"],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T10:04:03Z"],["dc.date.available","2018-11-07T10:04:03Z"],["dc.date.issued","2015"],["dc.description.abstract","BackgroundCold atmospheric plasma (CAP, i.e. ionized air) is an innovating promising tool in reducing bacteria. ObjectiveWe conducted the first clinical trial with the novel PlasmaDerm((R)) VU-2010 device to assess safety and, as secondary endpoints, efficacy and applicability of 45s/cm(2) cold atmospheric plasma as add-on therapy against chronic venous leg ulcers. MethodsFrom April 2011 to April 2012, 14 patients were randomized to receive standardized modern wound care (n=7) or plasma in addition to standard care (n=7) 3x per week for 8weeks. The ulcer size was determined weekly (Visitrak((R)), photodocumentation). Bacterial load (bacterial swabs, contact agar plates) and pain during and between treatments (visual analogue scales) were assessed. Patients and doctors rated the applicability of plasma (questionnaires). ResultsThe plasma treatment was safe with 2 SAEs and 77 AEs approximately equally distributed among both groups (P=0.77 and P=1.0, Fisher's exact test). Two AEs probably related to plasma. Plasma treatment resulted in a significant reduction in lesional bacterial load (P=0.04, Wilcoxon signed-rank test). A more than 50% ulcer size reduction was noted in 5/7 and 4/7 patients in the standard and plasma groups, respectively, and a greater size reduction occurred in the plasma group (plasma -5.3cm(2), standard: -3.4cm(2)) (non-significant, P=0.42, log-rank test). The only ulcer that closed after 7weeks received plasma. Patients in the plasma group quoted less pain compared to the control group. The plasma applicability was not rated inferior to standard wound care (P=0.94, Wilcoxon-Mann-Whitney test). Physicians would recommend (P=0.06, Wilcoxon-Mann-Whitney test) or repeat (P=0.08, Wilcoxon-Mann-Whitney test) plasma treatment by trend. ConclusionCold atmospheric plasma displays favourable antibacterial effects. We demonstrated that plasma treatment with the PlasmaDerm((R)) VU-2010 device is safe and effective in patients with chronic venous leg ulcers. Thus, larger controlled trials and the development of devices with larger application surfaces are warranted."],["dc.identifier.doi","10.1111/jdv.12490"],["dc.identifier.isi","000346733800024"],["dc.identifier.pmid","24666170"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38612"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1468-3083"],["dc.relation.issn","0926-9959"],["dc.title","Alleviation of chronic venous leg ulcers with a hand-held dielectric barrier discharge plasma generator (PlasmaDerm (R) VU-2010): results of a monocentric, two-armed, open, prospective, randomized and controlled trial (NCT01415622)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","199"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Annals of Neurology"],["dc.bibliographiccitation.lastpage","210"],["dc.bibliographiccitation.volume","72"],["dc.contributor.author","Sühs, K.-W."],["dc.contributor.author","Hein, K."],["dc.contributor.author","Sättler, M. B."],["dc.contributor.author","Görlitz, A."],["dc.contributor.author","Ciupka, C."],["dc.contributor.author","Scholz, K."],["dc.contributor.author","Käsmann-Kellner, B."],["dc.contributor.author","Papanagiotou, P."],["dc.contributor.author","Schäffler, N."],["dc.contributor.author","Restemeyer, C."],["dc.contributor.author","Bittersohl, D."],["dc.contributor.author","Hassenstein, A."],["dc.contributor.author","Seitz, B."],["dc.contributor.author","Reith, W."],["dc.contributor.author","Fassbender, K."],["dc.contributor.author","Hilgers, R."],["dc.contributor.author","Heesen, C."],["dc.contributor.author","Bähr, M."],["dc.contributor.author","Diem, R."],["dc.date.accessioned","2017-09-07T11:48:29Z"],["dc.date.available","2017-09-07T11:48:29Z"],["dc.date.issued","2012"],["dc.description.abstract","Objective: Based on findings in animal models of autoimmune optic nerve inflammation, we have assessed the safety and efficacy of erythropoietin in patients presenting with a first episode of optic neuritis. Methods: Patients with optic neuritis who attended the University Hospitals of Homburg/Saar, Gottingen, or Hamburg (Germany) were included in this double-blind, placebo-controlled, phase 2 study (ClinicalTrials.gov, NCT00355095). They were randomly assigned to groups receiving either 33,000IU recombinant human erythropoietin intravenously daily for 3 days or placebo as an add-on therapy to methylprednisolone. The primary outcome parameter was change in retinal nerve fiber layer (RNFL) thickness after 16 weeks. Secondary outcome parameters included optic nerve atrophy as assessed by magnetic resonance imaging, and changes in visual acuity, visual field, and visual evoked potentials (VEPs). Results: Forty patients were assigned to the treatment groups (21/19 erythropoietin/placebo). Safety monitoring revealed no relevant issues. Thirty-seven patients (20/17 erythropoietin/placebo) were analyzed for the primary endpoint according to the intention-to-treat protocol. RNFL thinning was less apparent after erythropoietin treatment. Thickness of the RNFL decreased by a median of 7.5 mu m by week 16 (mean +/- standard deviation, 10.55 +/- 17.54 mu m) compared to a median of 16.0 mu m (22.65 +/- 29.18 mu m) in the placebo group (p = 0.0357). Decrease in retrobulbar diameter of the optic nerve was smaller in the erythropoietin group (p = 0.0112). VEP latencies at week 16 were shorter in erythropoietin-treated patients than in the placebo group (p = 0.0011). Testing of visual functions revealed trends toward an improved outcome after erythropoietin treatment. Interpretation: These results give the first indications that erythropoietin might be neuroprotective in optic neuritis. ANN NEUROL 2012;72:199210."],["dc.identifier.doi","10.1002/ana.23573"],["dc.identifier.gro","3142489"],["dc.identifier.isi","000307946000010"],["dc.identifier.pmid","22926853"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8846"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","0364-5134"],["dc.title","A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e34351"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Lahno, Rosine"],["dc.contributor.author","Haase, Beatrice"],["dc.contributor.author","Weber-Krueger, Mark"],["dc.contributor.author","Seegers, Joachim"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Wohlfahrt, Janin"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Kermer, Pawel"],["dc.contributor.author","Vollmann, Dirk"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Groeschel, Klaus"],["dc.contributor.author","Stahrenberg, Raoul"],["dc.date.accessioned","2017-09-07T11:48:54Z"],["dc.date.available","2017-09-07T11:48:54Z"],["dc.date.issued","2012"],["dc.description.abstract","Background and Purpose: Diagnosis of paroxysmal atrial fibrillation (AF) can be challenging, but it is highly relevant in patients presenting with sinus rhythm and acute cerebral ischemia. We aimed to evaluate prospectively whether natriuretic peptide levels and kinetics identify patients with paroxysmal AF. Methods: Patients with acute cerebral ischemia were included into the prospective observational Find-AF study. N-terminal pro brain-type natriuretic peptide (NT-proBNP), brain-type natriuretic peptide (BNP) and N-terminal pro atrial-type natriuretic peptide (NT-proANP) plasma levels were measured on admission, after 6 and 24 hours. Patients free from AF at presentation received 7 day Holter monitoring. We prospectively hypothesized that patients presenting in sinus rhythm with NT-proBNP>median were more likely to have paroxysmal AF than patients with NT-proBNPmedian (239 pg/ml), 17.9% had paroxysmal AF in contrast to 7.4% with NT-proBNP<239 pg/ml (p = 0.025). The ratio of early (0 h) to late (24 h) plasma levels of NT-proBNP showed no difference between both groups. For the detection of paroxysmal atrial fibrillation, BNP, NT-proBNP and NT-proANP at admission had an area under the curve in ROC analysis of 0.747 (0.663-0.831), 0.638 (0.531-0.744) and 0.663 (0.566-0.761), respectively. In multivariate analysis, BNP was the only biomarker to be independently predictive for paroxysmal atrial fibrillation. Conclusions: BNP is independently predictive of paroxysmal AF detected by prolonged ECG monitoring in patients with cerebral ischemia and may be used to effectively select patients for prolonged Holter monitoring."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2012"],["dc.identifier.doi","10.1371/journal.pone.0034351"],["dc.identifier.gro","3142549"],["dc.identifier.isi","000305336600027"],["dc.identifier.pmid","22509292"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7572"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8912"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 2.5"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.5"],["dc.title","Natriuretic Peptides for the Detection of Paroxysmal Atrial Fibrillation in Patients with Cerebral Ischemia - the Find-AF Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","PII S0304-3959(01)00444-4"],["dc.bibliographiccitation.firstpage","189"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Pain"],["dc.bibliographiccitation.lastpage","196"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Leibing, Eric"],["dc.contributor.author","Leonhardt, Urs"],["dc.contributor.author","Köster, Georg"],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Rosenfeldt, Joerg-André"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2021-06-01T10:50:15Z"],["dc.date.available","2021-06-01T10:50:15Z"],["dc.date.issued","2002"],["dc.description.abstract","There is some evidence for the efficacy of acupuncture in chronic low-back pain (LBP), but it remains unclear whether acupuncture is superior to placebo. In a randomized. blinded, placebo-controlled trial, we evaluated the effect of traditional acupuncture in chronic LBP. A total of 131 consecutive out-patients of the Department of Orthopaedics, University Goettingen, Germany, (age = 48.1 years, 58.5% female, duration of pain: 9.6 years) with non-radiating LBP for at least 6 months and a normal neurological examination were randomized to one of three groups over 12 weeks. Each group received active physiotherapy over 12 weeks. The control group (n = 46) received no further treatment, the acupuncture group (it = 40) received 20 sessions of traditional acupuncture and the sham-acupuncture group (it = 45) 20 sessions of minimal acupuncture, Changes from baseline to the end of treatment and to 9-month follow-up were assessed in pain intensity and in pain disability, and secondary in psychological distress and in spine flexion, compared by intervention groups. Acupuncture was superior to the control condition (physiotherapy) regarding pain intensity (P = 0.000), pain disability (P = 0.000), and psychological distress (P = 0,020) at the end of treatment. Compared to sham-acupuncture, acupuncture reduced psychological distress (P = 0.040) only. At 9-month follow-up, the superiority of acupuncture compared to the control condition became less and acupuncture was not different to sham-acupuncture. We found a significant improvement by traditional acupuncture in chronic LBP compared to routine care (physiotherapy) but not compared to sham-acupuncture. The trial demonstrated a placebo effect of traditional acupuncture in chronic LBP. (C) 2002 International Association for the Study of Pain. Published by Elsevier Science B.V. All rights reserved."],["dc.identifier.doi","10.1016/S0304-3959(01)00444-4"],["dc.identifier.isi","000175738800021"],["dc.identifier.pmid","11932074"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86585"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0304-3959"],["dc.title","Acupuncture treatment of chronic low-back pain – a randomized, blinded, placebo-controlled trial with 9-month follow-up"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","ISRN Pediatrics"],["dc.bibliographiccitation.lastpage","6"],["dc.bibliographiccitation.volume","2012"],["dc.contributor.author","Gross, Oliver"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Görlitz, Anke"],["dc.contributor.author","Gavénis, Karsten"],["dc.contributor.author","Ahmed, Raees"],["dc.contributor.author","Dürr, Ulrike"],["dc.date.accessioned","2019-07-09T11:54:04Z"],["dc.date.available","2019-07-09T11:54:04Z"],["dc.date.issued","2012"],["dc.description.abstract","Introduction. Retrospective observational data show that ACE-inhibitor therapy delays renal failure and improves life expectancy in Alport patients with proteinuria. The EARLY PRO-TECT Alport trial assesses the safety and efficacy of early therapy onset with ramipril in pediatric Alport patients.Methods and analysis. This double-blind, randomized, placebo-controlled, multicenter phase III trial (NCT01485978; EudraCT-number 2010-024300-10) includes 120 pediatric patients aged 24 months to 18 years with early stages of Alport syndrome (isolated hematuria or microalbuminuria). From March 2012, up to 80 patients will be randomized 1:1 to ramipril or placebo. In the event of disease progression during 3-year treatment, patients are unblinded and ramipril is initiated, if applicable. Approximately 40 patients receive open-label ramipril contributing to the safety database. Primary endpoints are “time to progression to next disease level” and “incidence of adverse drug events before disease progression.” Treatment effect estimates from the randomized comparison and Alport registry data will be combined in supportive analyses to maximize evidence. Conclusion. Without this trial, ACE inhibitors may become standard off-label treatment in Alport syndrome without satisfactory evidence base. The results are expected to be of relevance for therapy of all pediatric patients with kidney disease, and the trial protocol might serve as a model for other rare pediatric glomerulopathies."],["dc.identifier.doi","10.5402/2012/436046"],["dc.identifier.fs","587146"],["dc.identifier.pmid","22811928"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8396"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60563"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2090-4703"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","255"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Der Schmerz"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Ensink, FBM"],["dc.contributor.author","Bautz, M. T."],["dc.contributor.author","Voss, M. C."],["dc.contributor.author","Gorlitz, A."],["dc.contributor.author","Hanekop, Gerd-Gunnar"],["dc.date.accessioned","2018-11-07T10:18:07Z"],["dc.date.available","2018-11-07T10:18:07Z"],["dc.date.issued","2002"],["dc.description.abstract","Introduction. Palliative care in Germany fails to reach established standards. To improve this situation the Chamber of Physicians of Lower-Saxony initiated SUPPORT in 1995. Prior to interventions structural quality of care was evaluated, specifically the rate of availability of opioid-prescription-forms and the ability to treat chronic pain (defined as a construct of knowledge, attitudes and skills) were examined. Methods. The survey was carried out using a standardized questionnaire mailed to a representative stratified sample of 1200 physicians. Results. Out of 865 answering physicians (response rate 72.1%) only 36.9% had their own opioid-prescription-forms. Differentiations regarding to speciality, working place (clinic vs. private practice) and treatment of cancer pain patients during the last three months shows a better result for GPs (84.6%), internists (48.6%), gynecologists (51%) and pain specialists (66.7%). Only 33.1% of respondents claimed knowledge of the WHO-3-step-analgesic-ladder. Again the aforementioned differentiations yield somewhat better results for GPs (49.2%), internists (51.5%), gynecologists (34.7%) and pain specialists (55.6%), however only two thirds of these physicians were able to identify the correct number of steps of the WHO-algorithm. Conclusions. These results verify an insufficient structural quality in palliative care in Lower-Saxony. In the authors' opinion effective improvements can only be achieved by implementing a parallel strategy: improvement of basic knowledge in pain management with sufficient transfer of this knowledge into practice as well as raising the rate of availability of opioid-prescription-forms, and, on the other hand, establishing local palliative-care-teams with nursing and medical expertise with 24/7 on-demand availability to optimize palliative care."],["dc.identifier.doi","10.1007/s00482-002-0163-0"],["dc.identifier.isi","000177689000002"],["dc.identifier.pmid","12192434"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41365"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0932-433X"],["dc.title","Indicators of structural quality in palliative care for cancer pain patients in Lower-Saxony"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S34"],["dc.bibliographiccitation.journal","Multiple Sclerosis Journal"],["dc.bibliographiccitation.lastpage","S35"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Suehs, K.-W."],["dc.contributor.author","Hein, Katharina"],["dc.contributor.author","Saettler, M. B."],["dc.contributor.author","Ciupka, C."],["dc.contributor.author","Scholz, K."],["dc.contributor.author","Kaesmann-Kellner, Barbara"],["dc.contributor.author","Papanagiotou, Panagiotis"],["dc.contributor.author","Schaeffler, N."],["dc.contributor.author","Restemeyer, C."],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Hilgers, Ralf-Dieter"],["dc.contributor.author","Seitz, Bjoern"],["dc.contributor.author","Reith, W."],["dc.contributor.author","Fassbender, Klaus"],["dc.contributor.author","Baehr, M."],["dc.contributor.author","Heesen, Christoph"],["dc.contributor.author","Diem, Ricarda"],["dc.date.accessioned","2018-11-07T08:51:30Z"],["dc.date.available","2018-11-07T08:51:30Z"],["dc.date.issued","2011"],["dc.identifier.isi","000209137300053"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21948"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.publisher.place","London"],["dc.relation.issn","1477-0970"],["dc.relation.issn","1352-4585"],["dc.title","Erythropoietin as add-on therapy to methylprednisolone in patients with acute autoimmune optic neuritis: a randomised, double-blind, placebo-controlled, phase II parallel group study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","22"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","114"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Schubert, Joerg"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Nickelsen, Maike"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2018-11-07T11:21:57Z"],["dc.date.available","2018-11-07T11:21:57Z"],["dc.date.issued","2009"],["dc.format.extent","1312"],["dc.identifier.isi","000272725804044"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55894"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","51st Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","New Orleans, LA"],["dc.relation.issn","0006-4971"],["dc.title","Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]